| We will create a rational molecular profiling system and make the redevelopment of drugs, for which development has been stopped, as well as the procedures to move forward drugs that are under development on to clinical trials, more efficient. For that purpose, we have organized the following five teams: Quantitative Proteomics Team for deciding on compound targets and with the aim of investigating the mechanisms of medicinal efficacy; Computational Systems Biology Team to estimate action pathways and modes through mathematical analysis of compound profiling; Data Management and Integration Team for data management and the development of intellectual data analysis bases through the gathering of information; In-silico Drug Design Team to develop software for supporting drug discovery and to provide support for molecule designs for novel targets with an extensive number of case studies of applications; and Molecular-Recognition Structure Analysis Team with the aim of analyzing the modes of action of drugs through combinations of our unique NMR technology and various experiments. We are aiming to develop a rational drug discovery process that contributes to the short-term, effective revitalization of the sluggish state of drug discovery in Japan. |
 |